ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
Rhea-AI Summary
ImmuCell (Nasdaq: ICCC) reported unaudited results for the quarter ended June 30, 2026, with product sales rising 11.5% year over year to approximately $7.2 million. Gross margin declined to 33.9% from 43.7%, reflecting lower manufacturing volumes, scrap from a purchased-material quality issue, and cost shifts from the discontinued Re-Tain® program.
Net income increased to $1.8 million, or $0.20 per diluted share, versus $0.5 million, or $0.06 per basic and diluted share, aided by a one-time $2 million legal settlement from a former Re-Tain® contract manufacturer. Adjusted EBITDA grew to $2.7 million from $1.4 million. Cash and cash equivalents rose to $8.9 million, with operating cash flow of $6.6 million for the first half of 2026. The board authorized a two-phase First Defense® capacity expansion, totaling about $8.0 million ($3.5 million freeze-drying and $4.5 million colostrum processing), expected to take roughly 18 months and intended to be funded from cash on hand and cash from operations.
Positive
- Q2 2026 product sales up 11.5% to $7.2 million year over year
- Q2 2026 net income increased to $1.8 million from $0.5 million
- Q2 2026 diluted EPS rose to $0.20 from $0.06
- Q2 2026 adjusted EBITDA grew to $2.7 million from $1.4 million
- Cash balance increased to $8.9 million from $3.8 million at year-end 2025
- Board-approved First Defense® capacity expansion totaling about $8.0 million over ~18 months
Negative
- Q2 2026 gross margin declined to 33.9% from 43.7% year over year
- Cost of goods sold rose to $4.7 million from $3.6 million in Q2 2025
- Sales, marketing and administrative expenses increased to $2.4 million from $1.4 million in Q2 2025
News Explained
The
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 earnings report | Positive | +8.0% | Higher sales, profitability, gross margin, cash and settlement-supported capacity expansion |
| Mar 04 | Annual earnings report | Positive | -1.7% | Sales growth, margin improvement and narrower net loss |
| Nov 13 | Q3 earnings report | Negative | -10.7% | Quarterly sales declined despite improved profitability and nine-month margin recovery |
| Aug 14 | Q2 earnings report | Positive | -9.2% | Sales, net income, gross margin and cash improved year over year |
| May 14 | Q1 earnings report | Positive | +7.9% | Record quarterly net income, sales growth, margin improvement and higher adjusted EBITDA |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings reactions were mixed: three positive earnings announcements aligned with gains, while two positive announcements diverged with declines.
Key Terms
adjusted ebitda financial
gross margin financial
net working capital financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026.
Management’s Discussion:
“Today we are reporting net income of
“We saw an acceleration of our distributors’ out-the-door volume growth to
“The
ImmuCell recently announced the start of a capacity expansion investment to build its scalable manufacturing capability and ensure continued reliable supply of First Defense® using facilities and equipment associated with the discontinued Re-Tain® development program. “We previously announced an approximately
“Our strong commercial results reflect the benefits of restored product availability, investments in our commercial team and product portfolio, and a favorable domestic calf market,” said Olivier te Boekhorst, President and CEO. “We have been highly focused on ensuring reliable product supply and we are now well-positioned to meet customer demand while we execute a major capacity expansion program. Over the next 18 months, we expect to triple our capacity and improve long-term product economics. With greater confidence in our ability to meet customer demand, we are now prioritizing product cost improvements and strengthening colostrum sourcing capabilities to support scalable growth.”
Certain Financial Results:
- Second quarter 2026 product sales increased
11.5% , to approximately$7.2 million , compared to the quarter ended June 30, 2025. - Second quarter 2026 gross margin declined to
33.9% of product sales compared to43.7% during the quarter ended June 30, 2025. - Net income was
$1.8 million , or$0.20 per diluted share, during the quarter ended June 30, 2026 compared to a net income of$0.5 million , or$0.06 per basic share, during the quarter ended June 30, 2025. - Adjusted EBITDA (calculation methodology shown below) was
$2.7 million in the three months ended June 30, 2026, as compared to$1.4 million in the three months ended June 30, 2025. - During the three-month period ended June 30, 2026, ImmuCell received a legal settlement payment of
$2 million from our former Re-Tain® contract manufacturer, which contributed to reported net income and adjusted EBITDA.
Balance Sheet Data as of June 30, 2026:
- Cash and cash equivalents increased to
$8.9 million as of June 30, 2026, from$3.8 million as of December 31, 2025, such increase benefiting in part from the$2 million settlement payment. - Net working capital increased to approximately
$16.6 million as of June 30, 2026 from$13.0 million as of December 31, 2025. - Stockholders’ equity increased to
$31.4 million as of June 30, 2026 from$27.1 million as of December 31, 2025.
| Condensed Statements of Income (Unaudited) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| (In thousands, except per share amounts) | 2026 | 2025 | 2026 | 2025 | |||||||||||
| Product sales | |||||||||||||||
| Costs of goods sold | 4,749 | 3,627 | 10,449 | 8,340 | |||||||||||
| Gross profit | 2,437 | 2,818 | 7,094 | 6,172 | |||||||||||
| Sales, marketing and administrative expenses | 2,382 | 1,416 | 4,753 | 2,896 | |||||||||||
| Product development expenses | 120 | 832 | 437 | 1,589 | |||||||||||
| Other operating income | (2,000 | ) | - | (2,000 | ) | - | |||||||||
| Operating expenses | 502 | 2,248 | 3,190 | 4,485 | |||||||||||
| NET OPERATING INCOME | 1,935 | 570 | 3,904 | 1,687 | |||||||||||
| Other (expenses) income, net | (54 | ) | (66 | ) | (70 | ) | 266 | ||||||||
| INCOME BEFORE INCOME TAXES | 1,881 | 504 | 3,834 | 1,953 | |||||||||||
| Income tax expense | 46 | 2 | 58 | 4 | |||||||||||
| NET INCOME | |||||||||||||||
| Basic weighted average common shares outstanding | 9,065 | 9,031 | 9,055 | 9,006 | |||||||||||
| Basic net income per share | |||||||||||||||
| Diluted weighted average common shares outstanding | 9,189 | 9,031 | 9,127 | 9,006 | |||||||||||
| Diluted net income per share | |||||||||||||||
| Selected Balance Sheet Data (In thousands) (Unaudited) | |||||||
| As of | As of | ||||||
| June 30, 2026 | December 31, 2025 | ||||||
| Cash and cash equivalents | |||||||
| Inventory | |||||||
| Net working capital | |||||||
| Total assets | |||||||
| Stockholders' equity | |||||||
| Selected Cash Flow Data (In thousands) (Unaudited) | |||||||
| Six Months Ended June 30, | |||||||
| 2026 | 2025 | ||||||
| Operating Activities | |||||||
| Investing Activities | (901 | ) | (455 | ) | |||
| Financing Activities | (638 | ) | (480 | ) | |||
| Net Change in Cash | 5,053 | 2,240 | |||||
| Cash at Beginning of Period | 3,807 | 3,758 | |||||
| Cash at End of Period | |||||||
Non-GAAP Financial Measures: Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flow that either excludes or includes amounts that are not normally included in or excluded from the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP measures included in this press release should be considered in addition to, and not as a substitute for or superior to, the comparable measure prepared in accordance with GAAP.
We believe that considering the non-GAAP measure of Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) assists management and investors by looking at our performance across reporting periods on a consistent basis excluding certain charges from our reported income before income taxes. We calculate adjusted EBITDA as described in the following table and reconciled to the most comparable GAAP financial measure:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| (In thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||
| Net income | |||||||||||||||
| Income tax expense | 46 | 2 | 58 | 4 | |||||||||||
| Interest expense (excluding debt issuance and debt discount costs) | 92 | 114 | 189 | 231 | |||||||||||
| Depreciation | 471 | 663 | 999 | 1,335 | |||||||||||
| Amortization (including debt issuance and debt discount costs) | 3 | 16 | 7 | 31 | |||||||||||
| Stock-based compensation expense | 240 | 67 | 378 | 119 | |||||||||||
| Adjusted EBITDA | |||||||||||||||
During the six-month period ended June 30 2026, we received a legal settlement payment of
First Defense® Capacity Expansion:
In late December 2025 and early January 2026, we announced our plan to convert the former Re-Tain® facilities and most of the related equipment for increased production of our First Defense® product line. In June 2026, our Board of Directors authorized a manufacturing capacity expansion program to execute that strategy.
The first phase expands drying capacity by renovating the former Re-Tain® facility and adding a new freeze dryer with greater capacity and reliability than our current freeze-drying equipment. This phase is expected to take approximately 12 months and cost approximately
The goal of these capacity expansion investments is to further strengthen our ability to reliably manufacture First Defense® products to meet expected customer demand.
Webcast / Conference Call:
The Company will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to review the unaudited financial results for the quarter ended June 30, 2026. Interested parties may access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international).
The live webcast can be accessed at: https://app.webinar.net/EQx8PqBGe36
The live webcast will feature a set of accompanying presentation slides that will subsequently be available in the Investors section of the Company’s website at: https://immucell.com/investors/
A teleconference replay of the conference call will be available through August 21, 2026, by dialing (855) 669-9658 (toll free) or (412) 317-0088 (international) and utilizing replay access code #8659150.
A webcast replay will also be available at: https://app.webinar.net/EQx8PqBGe36
About ImmuCell:
ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense® line of products that provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours. Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at: http://www.immucell.com/investors.
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):
This Press Release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to:
- our business plans, goals and strategies;
- projections of future financial and operational performance, expense ratios and margins;
- future demand for our products, including the First Defense® product line;
- the sequence, duration, costs and goals of our program to repurpose our former Re-Tain® facility and equipment for First Defense® production; and cost recoveries on Re-Tain® equipment no longer in service;
- capital expenditures, contractual commitments, and the anticipated sources and uses of cash to fund them;
and any other statements that are not historical facts. projections about depreciation expense and its impact on income for book and tax return purposes; and any other statements that are not historical facts. These statements reflect management’s current expectations as of the date hereof, are based on management’s estimates, projections, beliefs and assumptions as of such date; and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to differ materially, including risks relating to: competition in our markets; customer acceptance and product performance; alignment between our manufacturing resources and product demand; supply chain disruptions affecting our operations and our customer and supplier relationships; the commercial and operational risks of our current and planned expansion of production capacity; difficulties or delays in development, testing, regulatory approval, production and marketing of our products, and other risks and uncertainties detailed from time to time in our filings with the Securities and Exchange Commission (SEC), including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. There can be no assurance that the risks or developments we anticipate will be those that actually affect us. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise.
| Contacts: | Olivier te Boekhorst, President and CEO |
| Timothy C. Fiori, Chief Financial Officer | |
| ImmuCell Corporation | |
| investor.relations@immucell.com | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| iccc@lythampartners.com | |
